Published in J Neurosurg on November 01, 2008
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro Oncol (2014) 1.03
Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol (2011) 1.02
Management of low-grade glioma. Curr Neurol Neurosci Rep (2010) 0.96
Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol (2013) 0.90
Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J Clin Neurosci (2013) 0.87
Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. Metabolites (2015) 0.83
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer (2012) 0.81
Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. Eur Radiol (2011) 0.81
Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database Syst Rev (2015) 0.81
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. J Neurooncol (2015) 0.80
Supratentorial gliomas in eloquent areas: which parameters can predict functional outcome and extent of resection? PLoS One (2013) 0.80
Resection probability maps for quality assessment of glioma surgery without brain location bias. PLoS One (2013) 0.78
The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible. Cost Eff Resour Alloc (2016) 0.78
Current treatment of low grade gliomas. Memo (2012) 0.77
Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol (2017) 0.76
Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma. Semin Radiat Oncol (2015) 0.75
Low-grade gliomas. J Neurosurg (2011) 0.75
Management of supratentorial recurrent low-grade glioma: A multidisciplinary experience in 35 adult patients. Oncol Lett (2017) 0.75
Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. J Neurooncol (2017) 0.75
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Corridors of migrating neurons in the human brain and their decline during infancy. Nature (2011) 4.12
Glioma extent of resection and its impact on patient outcome. Neurosurgery (2008) 4.02
Functional outcome after language mapping for glioma resection. N Engl J Med (2008) 4.01
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg (2003) 3.91
Inequality in early childhood: risk and protective factors for early child development. Lancet (2011) 3.48
A survey-based study of wrong-level lumbar spine surgery: the scope of the problem and current practices in place to help avoid these errors. World Neurosurg (2012) 3.37
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol (2004) 3.25
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2003) 3.20
Patterns of care for adults with newly diagnosed malignant glioma. JAMA (2005) 3.08
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
High gamma activity in response to deviant auditory stimuli recorded directly from human cortex. J Neurophysiol (2005) 2.88
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Categorical speech representation in human superior temporal gyrus. Nat Neurosci (2010) 2.67
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol (2007) 2.56
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976) (2011) 2.38
Efficacy and safety of surgical decompression in patients with cervical spondylotic myelopathy: results of the AOSpine North America prospective multi-center study. J Bone Joint Surg Am (2013) 2.36
Does vertebral level of pedicle subtraction osteotomy correlate with degree of spinopelvic parameter correction? J Neurosurg Spine (2010) 2.32
Anterior versus posterior surgical approaches to treat cervical spondylotic myelopathy: outcomes of the prospective multicenter AOSpine North America CSM study in 264 patients. Spine (Phila Pa 1976) (2013) 2.30
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Aberrant seizure-induced neurogenesis in experimental temporal lobe epilepsy. Ann Neurol (2006) 2.22
Comanagement of surgical patients between neurosurgeons and hospitalists. Arch Intern Med (2010) 2.22
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg (2010) 2.19
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Rates of new neurological deficit associated with spine surgery based on 108,419 procedures: a report of the scoliosis research society morbidity and mortality committee. Spine (Phila Pa 1976) (2011) 2.16
Modern surgical outcomes following surgery for sphenoid wing meningiomas. J Neurosurg (2013) 2.16
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg (2011) 2.14
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery (2014) 2.11
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol (2006) 2.11
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
Spatiotemporal dynamics of word processing in the human brain. Front Neurosci (2007) 2.09
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke (2003) 2.07
Complications of lumboperitoneal shunts. Neurosurgery (2007) 2.07
Multiple-day drainage when using bone morphogenic protein for long-segment thoracolumbar fusions is associated with low rates of wound complications. World Neurosurg (2012) 2.06
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery (2015) 2.06